secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0000950170-23-018807
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC reports Q1 cash $208.9M; three Phase 1b data readouts expected H2 2023
---------------------------------------------------------------------------

- Cash and investments $208.9M as of March 31, 2023; funds operations into H1 2025.
- R&D expenses $19.5M (up $2.7M YoY) driven by clinical and discovery program advancement.
- G&A expenses $6.2M, down $0.3M YoY.
- Initial Phase 1b data expected H2 2023 for ORIC-533 (myeloma), ORIC-114 (EGFR/HER2), and ORIC-944 (prostate).
- Preclinical data for ORIC-944 biomarker strategy and PLK4 program presented at AACR 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000095017023018807/0000950170-23-018807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000095017023018807/oric-20230508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-018807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer